Overview of Recent Updates in Bispecific Therapy in R/R MM

Opinion
Video

The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Discuss similarities/differences in mechanism of action, key efficacy endpoints and safety data:
      • Teclistamab 
      • MajesTEC-1 (NEJM 2022)
      • MajesTEC-1 Long-term Follow-up (ASCO 2024)
      Recent Videos
      “If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
      JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
      Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
      MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
      The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
      JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
      The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
      Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      Related Content
      Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

      Busulfan-Enhanced VRD Regimen Improves Efficacy in NDMM

      Roman Fabbricatore
      July 3rd 2025
      Article

      Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

      Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

      Roman Fabbricatore
      July 2nd 2025
      Article

      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

      FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

      Tim Cortese
      June 27th 2025
      Article

      The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

      More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.

      Isatuximab Combo Shows Preliminary Activity in Pretreated Multiple Myeloma

      Russ Conroy
      June 24th 2025
      Article

      More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.